
|Articles|June 10, 2019
Neuroprotective implant for treatment of glaucoma in phase II trial
Author(s)Julianne Mobilian
Here's the latest innovations at Neurotech Pharmaceuticals, Inc.
Advertisement
Rich Small, CPA, CEO of
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant
2
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
3
EyePoint receives second consecutive positive recommendation from DSMC
4
Defining Retinal Vascular Diseases AMD, DME, RVO
5


















































.png)


